Learn about KISQALI, a treatment option for HER+, HER2- early breast cancer (eBC) and metastatic breast cancer (mBC). See full Prescribing and Safety Info.
People also ask
What is Kisqali used for?
Is Kisqali like chemo?
What is the life expectancy with Kisqali?
Does Kisqali shrink tumors?
Kisqali (ribociclib) is a CDK4/6 inhibitor used to treat certain cases of estrogen-receptor-positive, HER2-negative breast cancer.
Sep 17, 2024 · Kisqali has been approved as a treatment for metastatic breast cancer (MBC) patients in 99 countries worldwide, including by the US FDA and the ...
Ribociclib
Medication
Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. Ribociclib is a kinase inhibitor. It was developed by Novartis and Astex Pharmaceuticals. Wikipedia
AHFS/Drugs.com: Monograph
ATC code: L01EF02 (WHO)
Elimination half-life: 32.0 (29.7–54.7) hrs
Metabolism: Liver (CYP3A4)
Other names: LEE 011
Protein binding: ~70%
Show more
Show less
Learn about KISQALI, a CDK4/6 inhibitor used to treat patients with HR+/HER2- metastatic breast cancer (mBC). See full Prescribing & Safety Information.
Sep 17, 2024 · The Food and Drug Administration approved ribociclib (Kisqali, Novartis Pharmaceuticals Corporation) with an aromatase inhibitor for the adjuvant treatment of ...
A drug used with an aromatase inhibitor or fulvestrant (a type of hormone therapy) to treat adults with certain types of hormone-receptor positive, ...
